SON

Sonoco Products Co. 10-Q Summary: Q2 2024

Business Context and Reporting Period

This filing covers the quarterly period ended June 30, 2024. Sonoco Products Company is a global designer and manufacturer of packaging products operating primarily through two reportable segments: Consumer Packaging and Industrial Paper Packaging. Effective January 1, 2024, the company restructured its reporting, integrating flexible and thermoformed packaging businesses into the Consumer Packaging segment and treating recycling operations within Industrial Paper Packaging as a procurement function rather than a sales channel.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Net sales decreased 4.8% in Q2 and 5.1% YTD compared to 2023. This was driven by the absence of sales from the divested Protexic business ($44.9M), the closure of a thermoformed plant ($33.7M), and the accounting change for recycling operations ($22.5M), partially offset by $163.7M in sales from acquisitions.
• Profitability Pressure: GAAP Operating Profit fell 25.3% in Q2 and 39.4% YTD. The decline is attributed to higher restructuring charges ($19.3M in Q2 vs. $6.1M prior year), increased acquisition/divestiture costs ($22.3M in Q2 vs. $4.5M prior year), and unfavorable price/cost dynamics.
• Segment Performance:
  • Consumer Packaging: Sales down 4.5%, but Operating Profit up 10.9% due to strong productivity gains.
  • Industrial Paper Packaging: Sales up 2.7%, but Operating Profit down 23.1% due to significant price/cost pressures ($46.5M impact) and higher employee costs.
  • All Other: Sales down 36.2% primarily due to the Protexic divestiture.
• Restructuring: Total restructuring and asset impairment charges were $50.9M YTD, compared to $34.9M in the prior year. This includes charges related to mill closures in Sumner, WA, and Kilkis, Greece.

Guidance, Outlook, and Risks

• Strategic Acquisitions: On June 22, 2024, Sonoco agreed to acquire Eviosys (a global metal packaging supplier) for approximately $3.9 billion. To fund this, the company secured a $4.0 billion bridge loan facility and a $700 million term loan facility (closed July 12, 2024).
• Divestitures: Completed the sale of the Protexic business in April 2024 for $80.3 million, with proceeds used to pay down debt.
• Capital Allocation: Net capital spending for 2024 is expected to be between $350 million and $375 million. The company expects to make approximately $12 million in additional pension contributions for the remainder of 2024.
• Risks and Contingencies:
  • Geopolitical/Economic: Exposure to highly inflationary economies in Turkey and Venezuela. The company recorded a $1.0M pretax charge related to Turkey in the first half of 2024.
  • Goodwill Impairment: Management noted that the goodwill balance of the Plastics-Medical reporting unit ($63.9M) is at risk of impairment if operations do not meet expectations.
  • Commodity Prices: Ongoing volatility in raw material and energy costs, though partially mitigated by hedging strategies.

Investor Verification Checklist

• Eviosys Acquisition Status: Verify the closing timeline and regulatory approval status for the $3.9 billion Eviosys deal.
• Debt Maturities: Confirm the company's ability to refinance or repay the $485 million in debt maturing within the next 12 months, including the $400 million 1.80% notes due in February 2025.
• Restructuring Execution: Monitor the execution of announced mill closures (Sumner, Kilkis) and the associated cash outflows for severance and asset write-downs.
• Industrial Paper Margins: Assess whether price/cost pressures in the Industrial Paper Packaging segment will persist or improve in subsequent quarters.
• Goodwill Valuation: Review future disclosures regarding the Plastics-Medical reporting unit for potential impairment charges.